Evidence map›Paper›PMID 42621973›Full record

ArticleInternational journal of chronic obstructive pulmonary disease2026

Questionnaire-Based Assessment of Physical Disability in COPD.

Joffroy Rogier, Alexandre Vivien, Loïs Bolko, Sandra Dury, Jean-Hugues Salmon, Valérian Dormoy, Julien Ancel, Gaëtan Deslee, Jeanne-Marie Perotin

Registry-linked trialAbstract read
In one paragraph

Article in International journal of chronic obstructive pulmonary disease, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT02924818 (Cohort for Research and Innovation in Chronic Inflammatory Respiratory Diseases), which is not on this map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT02924818 narecruitingnot on this map

Cohort for Research and Innovation in Chronic Inflammatory Respiratory Diseases: The RINNOPARI Project

TypeinterventionalSponsorCHU de ReimsRan2016 to 2036Enrolled225ConditionsChronic Inflammatory Pulmonary DiseasesArmsClinical assessment, questionnaires, pulmonary function test, blood test, microbiology
3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Joffroy RogierDepartment of Respiratory Diseases, University Hospital of Reims, Reims, France.
Alexandre VivienDepartment of Respiratory Diseases, Department of Occupational Health, University Hospital of Reims, Reims, France.
Loïs BolkoDepartment of Rheumatology, University of Reims Champagne-Ardenne, University Hospital of Reims, Reims, France.
Sandra DuryDepartment of Respiratory Diseases, University Hospital of Reims, Reims, France.
Jean-Hugues SalmonDepartment of Rheumatology, University of Reims Champagne-Ardenne, University Hospital of Reims, Reims, France.
Valérian DormoyUniversity of Reims Champagne-Ardenne, INSERM, P3Cell UMR-S1250, Reims, France; University Institute of France (IUF), Paris, France.ORCID 0000-0003-1725-371X
Julien AncelUniversity of Reims Champagne-Ardenne, INSERM, University Hospital of Reims, P3Cell UMR-S1250, Reims, France.ORCID 0000-0003-3128-9348
Gaëtan DesleeUniversity of Reims Champagne-Ardenne, INSERM, University Hospital of Reims, P3Cell UMR-S1250, Reims, France.
Jeanne-Marie PerotinUniversity of Reims Champagne-Ardenne, INSERM, University Hospital of Reims, P3Cell UMR-S1250, Reims, France.ORCID 0000-0001-7184-3767

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Purpose: Chronic Obstructive Pulmonary Disease (COPD) is characterized by a progressive limitation of exercise capacity and functional disability, induced by both airway obstruction, skeletal muscle dysfunction and comorbidities, contributing to the disease burden. The Health Assessment Questionnaire - Disability Index (HAQ-DI), a validated tool assessing functional disability in rheumatologic diseases, with higher scores reflecting more severe disability, may be of interest in COPD. This study aimed to assess functional disability in COPD using the HAQ-DI and its association with disease severity and burden. Patients and Methods: Mild to very severe COPD patients were included in the RINNOPARI prospective cohort (NCT02924818). Pulmonary function tests and 6-minute walking test (6MWT) results, HRCT emphysema quantification, and patient-reported outcomes, including mMRC, CAT, SGRQ, EQ-5D and SF-36, were recorded. Functional disability was assessed using the French version of the HAQ-DI. Results: A total of 117 patients were included, with a median HAQ-DI score of 0.38 [0.0-0.75]. HAQ-DI scores were significantly higher in COPD GOLD 3-4 (0.50 [0.13-0.75] vs 0.25 [0-0.63] in COPD GOLD 1-2, p = 0.015). HAQ-DI was associated with cardiovascular and depression comorbidities (p < 0.05), COPD clinical features (number of exacerbations, p = 0.015; mMRC dyspnea score, CAT score and 6MWT distance, all p < 0.001), and COPD burden as assessed by SF-36, SGRQ and HAD anxiety and depression scores, p < 0.001 for all. Multivariate analysis identified the 6MWT distance, CAT, SGRQ, and HAD-Depression scores as independent factors associated with HAQ-DI. We further identified a « High Functional Disability » (HFD) phenotype defined by HAQ-DI ≥ 1 (n = 20), and characterized by COPD poor prognosis markers and severe disease burden. Conclusion: The HAQ-DI is a feasible tool for screening functional disability in COPD. It allowed the identification of a « high-risk, high burden » phenotype, which could benefit from personalised management such as pulmonary rehabilitation and psychological support.

Indexed as

Disability EvaluationExercise ToleranceLungPulmonary Disease, Chronic ObstructiveAgedCost of IllnessFemaleFranceFunctional StatusHealth StatusHumansMaleMiddle AgedPatient Reported Outcome MeasuresPredictive Value of TestsPrognosisburdenfrailtyHAQ-DIhigh functional disabilitypatient-reported outcomesphenotyping

Identifiers

PMID42621973
PMCPMC13488665

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.